Vaccines: German CureVac only 47% effective. EU: we are following the dossier, we await evaluations by the EMA

BRUSSELS - "The European Commission and the Member States, in the Steering Board, are closely following the issue" of the reduced efficacy of the Curevac vaccine, and await "the evaluation of the EMA".

response to a question.

"The contract stipulated with the pharmaceutical company is available online, and also includes a series of clauses on the delivery deadlines", explains the spokesperson to those who ask if there is the possibility of terminating the contract.

"But - he adds - we are absolutely not conducting this type of discussion".

The German laboratory CureVac announced that its leading Covid-19 vaccine candidate showed only 47% effectiveness, according to analysis of a large-scale clinical study, and at this stage it does not meet the required criteria. The vaccine "has reached a preliminary efficacy of 47% against Covid-19, regardless of its severity, not meeting the established statistical criteria of success," said the laboratory that signed an important order contract with the European Union for this messenger RNA vaccine. 

Very strong sales on the Frankfurt Stock Exchange on CureVac after the German laboratory announced that its main candidate for the Covid-19 vaccine showed only 47% effectiveness: the pharmaceutical group's stock drops 48% to 42 euros. The EU Commission has also announced that it is monitoring the dossier and, according to the analysis of a large-scale clinical study, at this stage the candidate for the CureVac messenger RNA vaccine does not meet the required criteria.